Pharmexa discontinues Phase II trial of breast cancer vaccine

Based on preliminary results Pharmexa has decided to stop further recruitment of patients to the HER-2 Protein AutoVac(TM) (PX 104.1) Phase II trial. The preliminary data shows that the HER-2 Protein AutoVac(TM) vaccine was not able to slow down the cancer in the first 10 included patients. So far, a total of 14 patients with stage IV metastatic breast cancer have been treated with the vaccine. The remaining 4 patients will be treated according to the protocol before the trial is put on final hold

Jakob Schmidt, CEO in Pharmexa says: "We are disappointed about these results. It looks like the patients simply progress before the vaccine has a chance to work. Although the antibody data are interesting and the number of patients treated is small, the conclusion is clear: There is no basis for continuing this trial in very ill metastatic breast cancer patients. Either the patients must be healthier or the vaccine must work faster."

Source: Pharmexa